Hepatitis C virus (HCV) is an emerging global public health issue with particular relevance in multiply transfused renal dialysis patients. This cross-sectional study evaluated the prevalence and risk factors for HCV infection among renal dialysis patients in northern Alberta, Canada. Ninety-two percent of eligible patients (n = 336) provided informed consent to participate. Participants were interviewed to gather risk factor information and, using multiple logistic regression analysis with exact inference, a predictive model for HCV infection in this population was developed. The prevalence of HCV infection in the population was 6.5%, and all positive patients had at least one identifiable risk factor. The multivariate analysis showed that the risk of HCV infection was greater for those in the 18-55 years age category (odds ratio (OR) = 4.9, 95% confidence interval (Cl) 1.2-27.9), patients who had been on dialysis >5 years (OR = 3.7, 95% Cl 1.2-12.0), and patients who had >2 high risk lifestyle behaviors (OR = 5.0, 95% Cl 1.5-16.7). Transfusion prior to 1990 was marginally associated with HCV status (OR = 4.0,). This study documented previously unreported life-style risk factors for HCV infection in patients with renal failure, confirmed the expected decline in transfusion-acquired HCV infection in this population, and provided evidence against nosocomial transmission of HCV. Am J Epidemiol 1999; 150:58-66.
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Hepatitis C virus (HCV) is an emerging global public health issue with particular relevance in multiply transfused renal dialysis patients. This cross-sectional study evaluated the prevalence and risk factors for HCV infection among renal dialysis patients in northern Alberta, Canada. Ninety-two percent of eligible patients (n = 336) provided informed consent to participate. Participants were interviewed to gather risk factor information and, using multiple logistic regression analysis with exact inference, a predictive model for HCV infection in this population was developed. The prevalence of HCV infection in the population was 6.5%, and all positive patients had at least one identifiable risk factor. The multivariate analysis showed that the risk of HCV infection was greater for those in the 18-55 years age category (odds ratio (OR) = 4.9, 95% confidence interval (Cl) 1.2-27.9), patients who had been on dialysis >5 years (OR = 3.7, 95% Cl 1.2-12.0), and patients who had >2 high risk lifestyle behaviors (OR = 5.0, 95% Cl 1.5-16.7). Transfusion prior to 1990 was marginally associated with HCV status (OR = 4.0, 95% Cl 0.96-16.3). This study documented previously unreported life-style risk factors for HCV infection in patients with renal failure, confirmed the expected decline in transfusion-acquired HCV infection in this population, and provided evidence against nosocomial transmission of HCV. Am J Epidemiol 1999; 150:58-66. blood transfusion; cross infection; cross-sectional studies; dialysis; hepatitis C virus; prevalence; risk factors Hepatitis C virus (HCV) infection is the most common cause of acute and chronic hepatitis in dialysis patients (1) . The prevalence of HCV antibodies in hemodialysis units has been reported to range from 5 percent to 54 percent (2, 3) , in contrast to a prevalence of 0.3-1.5 percent in the general population (4) (5) (6) . Before the introduction of recombinant erythropoietin, blood transfusions were a common therapeutic approach to treat anemia in hemodialysis patients (7) . Besides the risk of HCV transmission via transfusion of blood and blood products, previous renal transplantation and/or insufficient infection control procedures in the hemodialysis facility itself might account for the high prevalence of HCV infection in these patients.
The recovery rate from HCV infection is low, and about 85 percent of those infected become chronic carriers (8) (9) (10) . Despite the reduced life expectancy in patients with chronic renal failure, early detection and treatment of chronic hepatitis should be considered to prevent progression to liver cirrhosis and hepatocellular carcinoma, and associated morbidity and mortality (11, 12) , especially in patients who are being assessed for transplantation.
Descriptive epidemiologic studies have been used to define high risk groups, and have identified specific risk factors within these groups. Among dialysis patients, the main risk factors for transmission are previous blood transfusions and possibly nosocomial infections within the dialysis environment (13, 14) . Fluctuating hepatitis C viremia with periods of undetectable HCV-RNA among hemodialysis patients has been documented (15) . HCV transmission dynamics are not completely understood, but peritoneal dialysis patients generally have a lower prevalence than hemodialysis patients (16) .
Determining the presence and risk factors for antibody to hepatitis C virus (anti-HCV) in dialysis patients is important for several reasons. First, dialysis patients are often candidates for kidney transplantation, which may be associated with worsening of liver lesions as a Hepatitis C Prevalence and Risk Factors in a Dialysis Population 59 result of immunosuppression (17) . Second, at least 50 percent of these patients may have normal serum transaminase activity despite biopsy-proven chronic hepatitis (18) , which makes serious liver disease difficult to identify early in this population. Third, viremic patients could be the source of nosocomial transmission of HCV in hemodialysis units (19) . Finally, interferon treatment may be of value before kidney transplantation (20, 21) . Prevention of HCV infection in patients with end-stage renal failure may be important in precluding the progression of liver disease in kidney transplant recipients as well as the risk of potential transmission of HCV in dialysis centers (22) . This paper reports the results of a cross-sectional study that examined the prevalence and risk factors of HCV infection in the dialysis population of the Northern Alberta Renal Program (NARP) in Alberta, Canada.
MATERIALS AND METHODS

Study population
On July 1, 1997, there were 416 patients in the NARP, a comprehensive program that includes all renal dialysis patients in northern Alberta. Prior to interview, five of them had been transplanted and 25 had died. A further 20 were unable to provide informed consent, leaving 366 eligible patients. All were approached and asked to participate in the study.
Three hundred and thirty-six patients, representing 92 percent of eligible patients aged 18 years and older, provided informed consent. The study protocol was approved by the Medical Ethics Review Board of the Faculty of Medicine at the University of Alberta. Participants and non-participants were comparable for age and sex. After obtaining the informed consent of patients, participants were interviewed and data abstracted from their medical records. The interviewer/data abstractor was blinded to participants' HCV status to the extent possible.
Participants were interviewed by the same interviewer using a questionnaire comprising demographic, dialysis-specific, medical history and life-style variables. The demographic variables included age, sex, country of birth, and ethnic background. Medical variables included a history of blood transfusions, surgery, medical treatment in a developing nation, jaundice, and abnormal liver function. Life-style factors, including injection drug use and sexual activity were also requested. A combination of in-person and telephone interviews was employed. No systematic differences were seen between the two interview methods, and interviewees were comparable for age and sex irrespective of interview method. Conforming with ethics requirements, patients were not required to answer every question on the questionnaire. Consequently, there were some missing responses, especially for "sensitive" life-style questions, although this represented no more than 8 percent for any one variable.
Because there was concern regarding self-reported transfusion history, blood bank records and all accessible patient medical records were thoroughly reviewed to provide accurate patient transfusion histories based on best available information. However, ten of the participants (six females, four males) who were enrolled in the NARP reported a history of blood transfusion prior to their enrollment that could not be documented in the blood bank or their medical records. In all cases, the transfusion occurred outside of the northern Alberta region. When the respondent was able to recall the year and place of transfusion prior to dialysis, the validity of the self-report was accepted. Included among these ten participants were five who received transfusions during surgery, one who received a transfusion following a motor vehicle collision, three who were transfused after a cesarean section, and one who received a transfusion as a result of cancer chemotherapy.
Laboratory methodology
Serum specimens from all patients were screened using a third generation ELISA UBI® HCV EIA 4.0 (United Biomedical Co., Ltd., Beijing, PR China). A second anti-HCV EIA screen using the Abbott IMx® microparticle enzyme immunoassay (Abbott Laboratories Ltd., Mississauga, Ontario) was performed on all sera repetitively reactive in the first screen. Specimens in both EIA screening which tested above previously determined threshold levels were considered anti-HCV positive. Specimens that were reactive only in the first screen or that fell below threshold values in the dual EIA algorithm were subjected to a supplemental assay, the LiaTek® HCV IE immunoblot assay (Organon Teknika, Scarborough, Ontario). This algorithm has been demonstrated to have comparable sensitivity and specificity to the use of a single EIA screening test and a supplementary immunoblot (23) .
Serum from all patients was also examined for HCV-RNA by a polymerase chain reaction (PCR) assay, the Amplicor™ HCV test (Roche Diagnostic Systems Inc., Nutley, New Jersey). Specimens which tested negative for anti-HCV were screened in pools of 20, while positive anti-HCV specimens were run individually. HCV status and dichotomous variables were assessed with the chi-square statistic. Chi-square for linear trend was used for associations between categorical variables and HCV status. When the expected number in any cell was less than five, a two-tailed Fisher's exact test was used. When comparing two-sample means, a two-sample Mest was conducted; Satterthwaite's method was employed when the data had unequal variances.
For binary outcome of whether or not the patient is infected with HCV, the logistic regression approach was adopted to establish a prediction model. A method of purposeful selection of variables to obtain a parsimonious model was performed. Some explanatory variables were originally continuous and were dichotomized according to clinically useful subgroups. Cut-points were chosen to optimize the number of participants per cell while providing logical dichotomies that were more relevant and meaningful. In the initial bivariate analysis, age was grouped in three categories. To enhance statistical power, age was dichotomized in the multivariate analysis. Preliminary bivariate analyses compared each covariate with HCV status. For the multiple logistic regression analysis, variables with bivariate p-values < 0.15, along with other clinically relevant variables, were considered important explanatory variables. The following explanatory variables were entered into a multiple logistic regression model, with HCV infection as the outcome variable: age group (18-55 years vs. 56 years and over), education (post-secondary vs. grade 12 and lower), length of time on dialysis (<5 years vs. >5 years), number of hours on hemodialysis (< 1,300 hours vs. >l,300 hours), serum alanine aminotransferase (ALT) in last 6 months (elevated vs. normal), blood transfusion, number of units transfused prior to 1990 (<4 units vs. >5 units), organ transplant before 1990, acupuncture, marijuana use, household contact with a known hepatitis case, multiple sexual partners, a history of high risk life-style behavior (yes/no), and >2 high risk life-style behaviors. Using p > 0.15 as a removal criterion, a parsimonious model was chosen by backward elimination. An exact method of inference (24) was used to determine the independent contributions of risk factors in predicting anti-HCV positivity, adjusting for all other significant covariates. Adjusted odds ratios and 95 percent confidence intervals were derived. The Russell and Rao similarity measure (25) was used to assess possible correlated effects of the variables that were included in the model with those that were not.
RESULTS
The mean age of the dialysis population (table 1) was 57.4 years. Sixty percent were males and the mean length of dialysis was less than 3.5 years. Sixty percent of participants were undergoing hemodialysis. The prevalence of anti-HCV antibody in this population was determined to be 6.5 percent (22/336). There was no case of anti-HCV negativity and HCV-RNA positivity. Seventy-seven percent (17/22) of anti-HCV positive patients also had detectable HCV-RNA. The prevalence of hepatitis B surface antigen (HbsAg) was only 1.2 percent (4/336) and independent of HCV infection. The mean age of anti-HCV positive patients was significantly different and in fact lower than that for anti-HCV negative patients (45.8 years vs. 58.2 years, t = 2.40, p = 0.023). The mean length of time on dialysis was snorter for anti-HCV negative patients (7.3 years vs. 3.1 years), but was not statistically significant (t -1.77, p = 0.091).
The prevalence of HCV infection was comparable for the three main hemodialysis centers in the NARP (9.5 percent vs. 9.6 percent vs. 9.3 percent). For the peritoneal dialysis center, the prevalence was 4.4 percent.
Gender and birth country did not vary with anti-HCV positivity (table 2) . Age was shown to be highly associated to HCV status in this population, with risk being the greatest for patients aged 40-54 years.
Among dialysis history determinants of HCV status (table 3) , an increasing length of time on dialysis, >2,800 hours of hemodialysis, elevated serum ALT >6 months, previous transplantation, and transplant before 1990 were found to be highly associated with HCV status. Several life-style factors were strongly associated with being hepatitis C positive (table 6) . These included the use of street drugs, sexual contact with a street drug user or a hepatitis case, household contact with a street drug user or a hepatitis case, and having been jailed.
Because the life-style factors were not mutually independent, and to facilitate the multivariate analysis, the number of high risk life-style behaviors per participant was calculated. A high risk life-style behavior was defined as having engaged in any one of the following activities: body piercing, tattooing, cocaine use, injection drug use, household contact with a street drug user, sexual contact with a street drug user, sex- ual contact with a known hepatitis case, a sexually transmitted disease history, being jailed, and participation in blood rituals.
Having at least one high risk life-style behavior yielded an odds ratio of 7.9 (95 percent Cl 2.8-25.7), indicating a significant association with anti-HCV positivity (table 7) . The number of high risk life-style behaviors showed a positive trend with anti-HCV positivity (chi-square trend = 27.4, p < 0.00001).
The multiple logistic regression analysis revealed significant predictors of HCV infection to include age, years on dialysis, and high risk life-style behavior (table 8) . Specifically, the odds ratio was 4.20 (95 percent Cl 1.10-24.32) for patients in the 18-55 years of age category compared with patients who were >55 years, 3.57 (95 percent Cl 1.13-11.52) for those who had been on dialysis for >5 years, and 7.56 (95 percent Cl 1.94-32.13) for patients who had engaged in >2 high risk life-style behaviors. The odds ratio for multiple (>5) transfusions prior to 1990 was 3.60 with a lower 95 percent confidence limit of 0.86. The Hosmer-Lemeshow test statistic (2.33, p > 0.68) indicated that the null hypothesis of goodness of fit was not rejected and the model was useful in predicting the outcome accurately.
Although the method of variable selection was purposeful, in that assessment of statistical, clinical, and biologic significance was made, it was important to examine whether the four factors that remained in the model could have other explanations related to those eliminated. This was investigated with the Russell and Rao similarity measure, which indicated that these four factors were not related to other factors not in the model, demonstrating there were no other possible explanations for the HCV status than that offered herein. The Russell and Rao measures ranged 0.007 to 0.148 at most. which might be useful more broadly in low prevalence areas. Because of the inherent differences that may exist in geographically and demographically dissimilar areas, these findings may not apply to other dialysis populations, and should be generalized only with caution. The low prevalence resulted in a small number of participants who were HCV positive, making some of the risk estimates unstable. A significant age difference between eligible and ineligible dialysis patients was found (mean age 57.2 years vs. 63.4 years, respectively, t = 2.21, p < 0.05). The ineligible patients were older, and given the lower prevalence of HCV infection documented in the older age group of participants, it is reasonable to expect that the actual prevalence within our dialysis population is lower than the 6.5 percent reported here. The burden of HCV infection was found to be greatest in patients aged 40-50 years, an age well below the mean age of NARP patients.
The prevalence of anti-HCV antibodies among dialysis patients in Northern Alberta appeared to be low compared with other dialysis centers (2, 26, 27) . In particular, HCV prevalence was well below that of the 10-20 percent quoted for North American centers (28) . Because HCV-RNA was not detected in any patient who was anti-HCV negative, the data suggest that renal dialysis patients with HCV infection are able to mount an immune response. Because highly sensitive, third generation tests were used to document the presence of anti-HCV antibodies, the low prevalence is unlikely to result from under ascertainment of infection, but rather reflects stringent infection control practices.
The fact that 68.2 percent (15/22) of the HCV-positive patients had normal ALT levels over a 6-month period emphasizes the fact that ALT cannot be used as a surrogate marker of HCV infection in dialysis patients. With 77 percent of positive patients being viremic (HCV-RNA detected) and two-thirds having normal ALT levels, a biopsy may be necessary to determine whether these patients have liver injury.
The finding that 77 percent of 22 anti-HCV positive dialysis patients had detectable HCV-RNA, and that serologic positivity correlated with length of time on dialysis raised the question of whether non-infected dialysis patients were at risk of nosocomial infection, and whether specific dialysis machines should be dedicated for use by anti-HCV positive patients. Several factors argue against this interpretation: 1) infection may have been acquired for many of these patients before they began dialysis; 2) similar prevalence of HCV was seen among the three main hemodialysis units; and 3) there was no statistically significant difference in HCV prevalence between the peritoneal dialysis patients (who dialyzed at home) and the hemodialysis patients (who dialyzed in outpatient facilities). This is consistent with other studies that have reported that adherence to the universal infection control guidelines in a dialysis population is sufficient to prevent nosocomial transmission of HCV (13, 29) . While the relation between length of time on dialysis and HCV infection could be viewed as supporting the possibility of nosocomial transmission, the relation probably arose from the lack of HCV screening prior to 1990. Given that baseline infection has been determined, prospective seroconversion studies can now be conducted to address specifically the issue of nosocomial transmission.
The published literature on anti-HCV among patients on dialysis have identified the risk factors to be transfusion history, dialysis history, previous organ transplantation, and nosocomial transmission (30) (31) (32) (33) . Some investigators (1, 13, 34) have reported injection drug use to be an additional risk factor among patients on dialysis. Nonetheless, there has been a distinct gap in the literature regarding other potential risk factors in dialysis patients. This study documented previously unreported life-style risk factors for HCV infection in patients with renal failure.
In the NARP, all HCV-infected patients (n = 22) had either a high risk life-style behavior (n = 16) or a transfusion history prior to 1990 (n -6). Bivariate analyses suggested that high risk life-style behavior was more strongly associated with HCV status than transfusion history, even transfusions prior to 1990. The multiple logistic analysis corroborated this observation, and indicated that high risk life-style factors remained significantly associated with HCV status while multiple transfusions prior to 1990 did not. However, the relatively high odds ratio for multiple transfusions prior to 1990 is highly suggestive of an independent effect of transfusion-related infection after controlling for high risk life-style behaviors. It should also be considered that the relation between high risk life-style behaviors and anti-HCV positivity might have been underestimated as patients could have withheld this sensitive information.
Age was significantly associated with HCV status in the bivariate analysis, and the odds ratio for males, relative to females, was 1.4 (95 percent CI 0.53^4.20). Gender did not contribute significantly to the multivariate model. Age, entered as a dichotomous variable, remained significantly associated with HCV infection in the multivariate model, perhaps reflecting other, unmeasured risk factors, or residual confounding from, for example, high risk life-style behaviors.
Self-reported transfusion histories could not be verified for 10 participants. The self-reports were accepted as reliable for those who recalled the time and cause of their transfusion(s). To assess the effect of potential misclassification introduced by this assumption, the multivariate analysis was repeated, excluding these 10 participants. Only minor changes were seen in the risk estimates and confidence intervals. All previously significant confidence intervals still excluded the null (data not shown).
This study documented the low prevalence of HCV infection in dialysis patients in northern Alberta and described the risk factors. Thorough review of all transfusion records and the use of highly sensitive tests for HCV infection permitted a valid assessment of the impact of transfusion prior to 1990 on risk of HCV infection. However, the dialysis population in 1997 probably includes relatively few patients who were in the NARP and received transfusions prior to 1990. Many of the patients who were transfused prior to 1990 (especially those multiply transfused) would have died. As a result, the risk estimates for patients transfused prior to 1990 accurately reflects the current situation, but may underestimate the historical impact of transfusion-related HCV infection in this population.
The data suggest that blood transfusions are no longer a risk factor for hepatitis C seroconversion and that the screening of blood donors for anti-HCV and high risk life-styles has had a significant impact on the transmission of HCV infection by blood products. It is worthwhile to note that within this multiple transfused population, risk-taking life-style behaviors are the most important predictors of hepatitis C risk.
